RIN3

Across TCGA pan-cancer cohorts, RIN3 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RIN3 data layer compared with 21 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher RIN3 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated RIN3 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, GBM, and LUAD are the cancer types where RIN3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	All	0.920	0.804	.004	11	view →
GBM	DFS	Quartile	All	0.653	0.851	.011	11	view →
LUAD	OS	Median	III,IV	0.298	0.808	.013	7	view →
HNSC	DFS	Quartile	All	0.890	1.000	.013	6	view →
LSCC	DFS	Median	II,III,IV	0.543	0.860	.009	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RIN3–PDAC (OS)

Open the PDAC breakdown →